Detalhe da pesquisa
1.
An IL-1ß-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.
Nat Immunol
; 25(5): 820-833, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38600356
2.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38084760
3.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38048557
4.
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Blood
; 141(6): 579-591, 2023 02 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36130300
5.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38697166
6.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica
; 2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38385280
7.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36528035
8.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37717583
9.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37269857
10.
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Blood
; 136(26): 3033-3040, 2020 12 24.
Artigo
Inglês
| MEDLINE | ID: mdl-33367546
11.
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
Int J Mol Sci
; 23(24)2022 Dec 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36555520
12.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34774221
13.
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Cancer
; 127(18): 3413-3421, 2021 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34181755
14.
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Br J Haematol
; 194(3): 496-507, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33724461
15.
The role of autologous stem-cell transplantation in multiple myeloma in 2021.
Curr Opin Oncol
; 33(6): 642-647, 2021 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34419954
16.
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Haematologica
; 106(8): 2054-2065, 2021 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33792221
17.
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica
; 106(11): 2799-2812, 2021 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34261295
18.
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 26(10): e247-e255, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32589921
19.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 393(10168): 253-264, 2019 01 19.
Artigo
Inglês
| MEDLINE | ID: mdl-30545780
20.
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
Haematologica
; 105(1): 193-200, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31221778